FindTrial
Sign In

Looking at the medical details and results of treatment in people with a rare type of uterine cancer that has a BCOR gene

Clinical Insights and Outcomes in BCOR-Positive Uterine Sarcoma - A Retrospective Analysis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/01/079392
Enrollment
20
Registered
2025-01-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C549- Malignant neoplasm of corpus uteri, unspecified

Interventions

Intervention1: NA: NA Intervention2: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All immunohistochemistry BCOR positive uterine sarcoma

Exclusion criteria

Exclusion criteria: 1. Inadequate tissue samples for BCOR immunohistochemistry. 2. Lack of essential clinical information.

Design outcomes

Primary

MeasureTime frame
1. To comprehensively characterize the clinicopathological features of BCOR immunohistochemistry-positive uterine sarcomas. 2. To assess the prognostic implications of BCOR expression in terms of overall survival, disease-free survival, and treatment response. 3.To analyze treatment patterns, including surgery, radiation, and chemotherapy, and evaluate their impact on patient outcomes. Timepoint: 1 Year—

Secondary

MeasureTime frame
To explore the genomic landscape of BCOR-positive uterine sarcomas and identify potential molecular correlates and therapeutic targets.Timepoint: 1 Year—

Countries

India

Contacts

Public ContactAnbarasan Sekar

Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre

anbarasan157@gmail.com8124227205

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026